Study of Cerebral Vascular Reserve Using Pharmacological Testing With Acetazolamide: A Non-Inferiority Study of PET Method Compared to Conventional Reference Scintigraphy
PET scan: 18F-FDG PET scans will be performed to assess cerebral vascular reserve. For exams involving stimulation with Acetazolamide (DIAMOX®), the radiopharmaceutical injection (18F-FDG or 99mTc-HMPAO) will start exactly 15 minutes after the Acetazolamide (DIAMOX®) injection.
Study summary
This study compares two methods for assessing brain blood flow. PET scan will be use with a drug called Acetazolamide and compare its effectiveness to the standard scintigraphy method. The goal is to see if the PET scan is just as good as the traditional method in measuring how well the brain's blood vessels respond to the drug.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Chronic stenosing cerebral vascular pathology (stenosis \> 70% on Doppler examination or angiography).
* Patient aged over 18 years.
* Patient who has voluntarily agreed to participate in the study and has signed the written informed consent.
* Patient affiliated with a social security system.
Exclusion Criteria:
* Patient with stenosis less than 70% on Doppler examination or angiography.
* Patient with a contraindication to 18F-FDG PET examinations: severe claustrophobia, poorly controlled diabetes during 18F-FDG PET examinations (fasting capillary blood glucose ≥ 11 mmol/L).
* Patient with a contraindication to scintigraphy.
* Patient with an allergy to sulfonamides (Acetazolamide DIAMOX®).
* Patient enrolled in another clinical study with a specified exclusion period.
* Minor patient.
* Patient unable to give informed consent.
* Vulnerable individuals
Primary outcome measure(s)
diagnostic performance of the 18F-FDG PET — 12 months The primary endpoint is the sensitivity of the examination in detecting a decrease in cerebral vascular reserve (CVR). The presence or absence of a decrease in CVR for each patient will be determined by clinical consensus, based in particular on spontaneous follow-up (clinical progression, cerebral ischemic episodes, etc.) and/or on the progression after revascularization in cases where it is performed.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.